Financial Investments and Yields - The company purchased low-risk short-term financial products with its own funds, including a 3 million RMB product with an annual yield of 2.685%-3.395%[3], a 2 million RMB product with an annual yield of 6.277%[3], and a 5 million RMB product with an annual yield of 2.41%-2.43%[3] Government Subsidies - The company received government subsidies totaling 7,745,053.89 RMB, including 6,433,052.27 RMB from VAT refunds and 470,000 RMB from the 2023 Technology Innovation Guidance Plan[4] - Government subsidies received totaled 7,744,876.50, compared to 4,718,381.07 in the previous year[21] - Government subsidies are recognized when the conditions attached are met and the subsidies are receivable. Monetary subsidies are measured at the actual amount received, while non-monetary subsidies are measured at fair value or nominal amount (1 yuan) if fair value cannot be reliably determined[80] - The company and its subsidiaries classify government subsidies as either asset-related or income-related. Asset-related subsidies are deferred and recognized over the useful life of the related asset, while income-related subsidies are recognized as income when received[80] Asset and Financial Position - The company's total assets increased to 276,828,764.33 RMB from 272,061,845.68 RMB, with current assets rising to 203,997,015.45 RMB from 195,819,839.52 RMB[6] - The company's cash and cash equivalents increased by 23,498,324.32 RMB, reaching 141,342,846.25 RMB at the end of the year[7] - The company's statutory surplus reserve increased by 1,565,168.97 RMB to 17,190,862.67 RMB[13] - The company's undistributed profit at the end of the year was 74,512,389.43 RMB, up from 64,439,262.25 RMB at the beginning of the year[14] - The company's cash balance at the end of the year was 141,342,846.25, compared to 117,844,521.93 at the beginning of the year[74] - The company's total asset impairment loss was -341,086.66, compared to -394,756.53 in the previous year[67] - The company's long-term equity investment in subsidiaries remained unchanged at 17,000,000.00[76] - The company's total number of employees increased from 232 to 244, with notable increases in doctoral (2 to 3) and master's degree holders (11 to 12)[157] - The company's total share capital at the end of the year is 106,182,400.00 shares[132] - The company's total employee benefits for the year amount to RMB 38,404,721.48[130] - The company's total assets were RMB 276.83 million, with a slight increase of 0.03% compared to the performance forecast[180] - Shareholders' equity attributable to the parent company was RMB 251.94 million, a decrease of 0.10% compared to the performance forecast[180] Profit and Loss - The company's net profit attributable to the parent company's owners was 11,638,296.15 RMB, compared to a loss of 4,244,228.99 RMB in the previous year[14] - The company's consolidated profit for the year amounted to 11,467,535.90, with an income tax expense calculated at the statutory/applicable tax rate of 1,720,130.39[58] - The impact of different tax rates applied by subsidiaries resulted in a reduction of 379,259.19 in income tax expense[58] - The use of previously unrecognized deferred tax assets for deductible losses had a negative impact of 2,086,427.02 on income tax expense[58] - The impact of unrecognized deferred tax assets for deductible temporary differences or losses was 2,791,725.62[58] - Net profit attributable to shareholders was RMB 11.64 million, a decrease of 2.22% compared to the performance forecast[180] - Net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 7.85 million, a decrease of 3.25% compared to the performance forecast[180] - Basic earnings per share were RMB 0.11, with no variance compared to the performance forecast[180] - Weighted average return on equity (pre-deduction) was 4.73%, a decrease of 2.87% compared to the performance forecast[180] - Weighted average return on equity (post-deduction) was 3.19%, a decrease of 3.92% compared to the performance forecast[180] Revenue and Income - Rental income from buildings amounted to 695,502.02[19] - Revenue for the year was RMB 96.58 million, with no variance compared to the performance forecast[180] Accounts Receivable and Bad Debt Provisions - Accounts receivable within 1 year amounted to 27,693,823.71, an increase from 24,851,515.50 in the previous year[41] - Accounts receivable aged 1-2 years decreased significantly to 6,603,330.50 from 25,143,144.29 in the previous year[41] - The company's top five accounts receivable and contract assets at year-end include Wuhan Jinmao Engineering Technology Co., Ltd. with a balance of 9,482,407.20 CNY, accounting for 18.89% of the total[50] - The company's accounts receivable are classified into categories based on the method of bad debt provision. As of the end of the reporting period, the total accounts receivable were 48,925,152.15 yuan, with a bad debt provision of 16,787,354.12 yuan, representing a provision ratio of 34.31%[96] - The company's bad debt provision for significant individual accounts receivable increased from 4,607,672.40 yuan at the beginning of the year to 5,214,627.20 yuan at the end of the year, with a provision ratio of 100%[96][98] - The company recovered or reversed bad debt provisions totaling 4,607,672.40 yuan during the year, primarily due to sales returns from Chongqing Taimin Pharmaceutical Co., Ltd., a subsidiary of Sinopharm Holding[98] - Accounts receivable and contract assets year-end balance totaled 29,944,083.42, with a bad debt provision of 8,945,558.25, accounting for 59.56% of the total[99] - The year-end balance of contract assets was 1,343,874.86, with a bad debt provision of 121,209.39, resulting in a net book value of 1,222,665.47[99] - Other receivables year-end balance was 766,933.08, with a bad debt provision of 176,716.50, representing a provision ratio of 23.04%[102] - The year-end balance of other receivables classified by aging showed 487,826.16 within 1 year, 121,100.00 for 1-2 years, and 158,006.92 for over 3 years[105] - Bad debt provision for accounts receivable is RMB 16,787,354.12, with a book value of RMB 32,137,798.03[126] - Accounts receivable at the end of the reporting period amounted to 32.14 million yuan, accounting for 11.61% of total assets, with 43.27% of receivables aged over 1 year[146] - The company has implemented strict bad debt provision policies for long-aged receivables to accurately reflect asset conditions[146] Leases and Rental Expenses - Short-term lease expenses for the current period were 923,035.72, up from 818,007.32 in the previous year[39] - Interest expenses on lease liabilities for the current period were 112,475.87, down from 177,512.55 in the previous year[39] - Total cash outflows related to leases were 2,772,761.25, slightly lower than the previous year's 2,822,199.34[39] - For leases, the company and its subsidiaries recognize a right-of-use asset and lease liability at the commencement date, except for short-term leases and leases of low-value assets[82] - The company and its subsidiaries measure lease liabilities at the present value of lease payments not yet paid at the commencement date, using the lease's implicit interest rate or the incremental borrowing rate if the implicit rate cannot be determined[91] - The company and its subsidiaries re-measure lease liabilities when there are changes in fixed payments, residual value guarantees, indices or rates used to determine lease payments, or the assessment of purchase, renewal, or termination options[92] - Prepaid rent at the end of the year is RMB 124,076.27, compared to RMB 151,930.17 at the beginning of the year[129] Investments and Equity - The company holds significant influence over its associates, typically when it owns between 20% and 50% of the voting rights, unless there is clear evidence that it cannot participate in the decision-making process[44] - The company uses the equity method to account for investments in joint ventures and associates, adjusting the carrying amount of the investment if the initial cost differs from the share of the net assets' fair value[45] - When the company loses control over a subsidiary, it reclassifies the remaining equity using the equity method if it retains significant influence or joint control, otherwise, it applies the financial instruments accounting standard[46] - The year-end balance of other equity instrument investments remained unchanged at 5,000,000.00, with no additional investments or reductions during the year[110] Fixed Assets and Depreciation - The company's fixed assets, including buildings and equipment, are depreciated using the straight-line method with a residual value rate of 5% and an annual depreciation rate of 4.75% for buildings[51][52] - The year-end book value of fixed assets, including production equipment and office equipment, totaled 44,911,364.08, a slight increase from the previous year's 44,760,875.04[113] Cash Flow and Operating Activities - The company's net cash flow from operating activities was 32,050,406.98, a significant increase from the previous year's 6,984,399.12[74] - The company's cash and cash equivalents increased by 23,498,324.32 RMB, reaching 141,342,846.25 RMB at the end of the year[7] - The company defines cash and cash equivalents as cash on hand and deposits that are readily available for payment, as well as short-term investments with a maturity of no more than three months[56] Tax and Incentives - The company was re-certified as a high-tech enterprise in 2023, enjoying a reduced corporate income tax rate of 15% from 2023 to 2025[146] - The company's subsidiaries, Yichuang Medical and Shenzhen Yichuang, enjoy tax incentives for small and micro enterprises, including a 50% reduction in resource tax, urban maintenance and construction tax, property tax, urban land use tax, stamp tax, farmland occupation tax, education surcharge, and local education surcharge[94] - The company and its subsidiaries recognize deferred tax liabilities for all taxable temporary differences except those arising from initial recognition of goodwill or transactions that do not affect accounting profit or taxable income[81] R&D and Innovation - R&D expenditure for the current period is RMB 22,941,404.20, accounting for 23.75% of operating revenue[135] - The company's R&D expenditure decreased from RMB 25,224,420.88 in the previous period to RMB 22,941,404.20 in the current period[135] - The company has 7 R&D projects in 2023, with 6 focused on digital human projects and 1 on a subsidiary project in Shenzhen[164] - The "High-Definition Digital Human R&D and Industrialization Project" has been upgraded and is set to launch in 2024[164] - The "Digital Human Anatomy System" supports a comprehensive teaching platform covering pre-class, in-class, and post-class activities[164] - The "Digital Human Cloud Platform" has been accessed by over 58,000 students and 3,000 teachers[164] - The company's R&D team has accumulated extensive expertise in medical imaging, computer science, and clinical experience[167] - The company has established a comprehensive R&D management system to ensure project execution and quality[167] - The company's R&D expenses in 2023 were 22.94 million yuan, accounting for 23.75% of the operating revenue[164] - The company has a strong R&D team of over 100 members, covering expertise in computer technology and medicine, and possesses advanced digital anatomy technology platforms, including data acquisition, 3D modeling, and virtual reality technologies[197] - The company's "High-Definition Digital Human Virtual Anatomy Table System" and "Digital Human High-Definition Tomography 3D Printing Model" have been recognized as reaching international advanced and leading levels, respectively, by the Chinese Anatomical Society[197] - The company has launched the Digital Human Cloud Platform, addressing challenges in hybrid online and offline teaching, resource shortages, and uneven distribution of teaching resources, supporting new educational models like flipped classrooms[197] - The company has formed R&D teams with prestigious medical institutions such as the Army Medical University and Shandong University, integrating computer information technology with traditional medicine to develop innovative products[197] - The company holds 14 invention patents and 71 copyrights, with R&D investment exceeding 15% of operating revenue in recent years[199] - The company has won the Shandong Provincial Science and Technology Progress Third Prize in 2014 and the National Teaching Achievement Second Prize in 2018[199] Corporate Governance and Shareholding - The company's controlling shareholder and actual controller, Xu Yifa, directly holds 40.85% of the shares and controls a total of 41.71% of the company's shares[149] - The top ten shareholders collectively hold 55.08% of the company's shares, with no related party relationships among them[148] - Xu Yifa has served as the company's chairman since 2015 and continues to hold this position[149] - The company's board of directors approved the conclusion of some fundraising projects and the permanent replenishment of surplus funds on December 26, 2023[152] - The company's third board of supervisors approved the 2023 semi-annual report and summary on August 24, 2023[152] - The company's 2022 annual report, financial report, and profit distribution plan were approved at the 2022 annual shareholders' meeting on May 22, 2023[152] - The company revised several governance-related systems, including the "Articles of Association," "Board of Directors System," and "Supervisory Board System," during the reporting period[155] - The company's core employees' changes had no significant impact, and no specific measures were taken[158] - The company did not implement any equity incentive plans during the reporting period[160] - The company did not engage in any labor outsourcing during the reporting period[161] Market and Product Development - The company's main products include digital medical education products, life science popularization products, and interactive smart all-in-one machines[186] - The company has established a comprehensive R&D management system, including regulations on R&D projects, documentation, product naming, and review processes, ensuring the execution of R&D projects through stages such as initiation, implementation, and acceptance[192] - The company has collaborated with domestic medical universities, including Shandong University and Inner Mongolia Medical University, to develop high-precision digital human products, achieving high-definition human tomography data acquisition and processing, and has begun product development for clinical diagnostic assistance and sports anatomy[192] - The company's products are widely used in over 500 medical institutions and have been piloted in more than 30 countries overseas, with plans to expand further through promotional activities[197] - The company is focusing on strengthening its market presence in the medical education sector, optimizing product quality, and enhancing core competitiveness to effectively respond to market competition[192] - The company is expanding its overseas medical education market in line with the national "Belt and Road" strategy, aiming to capitalize on historical development opportunities[192] - The company has completed the design and implementation of life science museums in multiple medical universities, leveraging its data and technological advantages in digital medicine[199] - The company's interactive smart all-in-one machine, produced by its wholly-owned subsidiary Shenzhen Yichuang, features high-quality touch panels and is used in various scenarios including education, exhibitions, and video conferencing[199] - The company has established 12 provincial offices nationwide, covering over 60% of the market in medical colleges and universities, solidifying its leading position in the digital anatomy field[199] - The company's core team possesses extensive expertise in computer science and medicine, enabling efficient and precise services[199] - The company plans to expand its business scope from medical education to clinical medicine and public health[199] - The company's products and solutions are highly aligned with the high data professionalism requirements of medical universities[199] - The company has a mature sales network and a complete service closed-loop, with high brand recognition and reputation in the market[199] - The company's technological innovation and brand advantages provide a solid foundation for its high-quality development[199] Risk Management - The company faces risks related to intellectual property infringement and has implemented measures such as patent applications and employee confidentiality agreements[146] - Core technical personnel retention is a key risk, with the company implementing competitive compensation and performance evaluation systems to mitigate this[146] - The company is exposed to risks from changes in tax incentives for software and integrated circuit industries[146] - The company has strengthened credit management and collection systems to reduce accounts receivable risks[146] Fundraising and Projects - The company's "Digital Human Cloud Platform Construction Project" was completed and reached the intended usable state on December 21, 2023, with a remaining fund of 3,795,985.23 yuan (including interest and financial income) permanently replenishing working capital[154] - The company extended the construction period of the "High-Definition Digital Human R&D and Industrialization Construction Project" to December 31, 2024, without changing the funding purpose or investment scale[154] Events and Recognition - The company showcased new technologies and products at the 59th China Higher Education Expo in April[168] - The company hosted the first National Medical College Students' Morphology Reading and Human Anatomy Specimen Identification Skills Competition in May[168] - The company's "High-Definition Digital Human Virtual Anatomy System V1.0" was recognized as a 2023 Shandong Famous Brand[174] - The company's "High-Definition Digital

北京浩天(济南)律师事务所 关于山东数字人科技股份有限公司 2024 年第二次临时股东大会的 法律意见书 济南市高新区经十东路 7000 号高新区汉峪金谷 A3-5 栋 16 层 邮编：250101 传真:0531-88876907 电话: 0531-88876911 法律意见书 北京浩天(济南)律师事务所 关于山东数字人科技股份有限公司 2024 年第二次临时股东大会的 法律意见书 致:山东数字人科技股份有限公司 经核查,本次股东大会由公司第三届董事会召集。公司董事会于 2024年 3 月 28 日召开第三届董事会第十七次会议,审议通过了《召开山东数字人科技股 份有限公司 2024 年第二次临时股东大会》的议案。公司已于 2024年 3 月 29 日 北京浩天(济南)律师事务所(以下简称"本所")接受山东数字人科技股 份有限公司 (以下简称"公司")的委托,指派本所律师出席公司 2024年第二 次临时股东大会(以下简称"本次股东大会"),并根据《公司法》《证券法》 等现行相关法律、法规、规章、其他规范性文件以及《山东数字人科技股份有限 公司章程》(以下简称"《公司章程》")的相关规定出具本法律意见书。 根据 ...

山东数字人科技股份有限公司 根据《上市公司独立董事管理办法》、《北京证券交易所股票上市规则（试 行）》及《北京证券交易所上市公司持续监管指引第 1 号—独立董事》等有关 规定，审计委员会成员应当为不在上市公司担任高级管理人员的董事，公司于 2023 年 10 月 25 日召开第三届董事会第十四次会议，同意对公司第三届董事会 审计委员会部分委员进行调整，董事会审计委员会由李增春先生、李承润先生、 徐以发先生三名成员组成，其中独立董事占审计委员会成员总数的 2/3，主任 委员由具备会计资格的独立董事李增春先生担任。审计委员会成员符合监管要 求及《公司章程》等相关文件的规定。 证券代码：835670 证券简称：数字人 公告编号：2024-026 董事会审计委员会 2023 年度履职情况报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 山东数字人科技股份有限公司（以下简称"公司"）第三届董事会审计委员 会根据《公司法》《证券法》《上市公司独立董事管理办法》《北京证券交易所股 票上市规则（试行）》及《北京证券 ...

证券代码：835670 证券简称：数字人 公告编号：2024-024 山东数字人科技股份有限公司 2023 年度独立董事述职报告（王莉） 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 本人王莉作为山东数字人科技股份有限公司（以下简称"公司"）的独立董 事，能够严格按照《中华人民共和国公司法》《北京证券交易所股票上市规则（试 行）》《北京证券交易所上市公司持续监管指引第 1 号——独立董事》等有关法 律、法规及《山东数字人科技股份有限公司章程》《山东数字人科技股份有限公 司独立董事工作制度》的相关规定和要求，忠实、勤勉、尽责地履行相关职责和 义务，积极出席相关会议，及时了解公司的生产经营信息，关注公司的发展状况， 认真审议董事会各项议案，并针对相关议案发表独立性意见，充分发挥独立董事 的独立性和专业性作用，切实维护了公司和股东尤其是中小股东的利益。现将本 人在 2023 年度履行职责的情况汇报如下： 一、出席情况 （一）出席董事会、股东大会的情况 2023 年度，公司共召开 5 次董事会会议、2 次股东 ...

证券代码：835670 证券简称：数字人 公告编号：2024-031 山东数字人科技股份有限公司拟续聘 2024 年度会计师事务所公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 涉及会计师事务所提供的资料、信息，会计师事务所保证其提供、报送或披 露的资料、信息真实、准确、完整，不得有虚假记载、误导性陈述或者重大遗漏。 重要内容提示： 拟聘任的会计师事务所：信永中和会计师事务所（特殊普通合伙） 组织形式：特殊普通合伙 注册地址：北京市东城区朝阳门北大街 8 号富华大厦 A 座 8 层 服务及收费情况：信永中和会计师事务所（特殊普通合伙）已为公司提供 1 年审计服务，上期审计收费 50 万元，本期审计收费 50 万元 一、拟续聘会计师事务所的基本情况 （一）机构信息 公司拟聘任信永中和会计师事务所（特殊普通合伙）为 2024 年年度的审计 机构。 1.基本信息 会计师事务所名称：信永中和会计师事务所（特殊普通合伙） 成立日期：2012 年 3 月 2 日 2022 年收入总额（经审计）：39.35 亿 ...

证券代码：835670 证券简称：数字人 公告编号：2024-033 山东数字人科技股份有限公司 一、会议召开基本情况 （一）股东大会届次 本次会议为 2023 年年度股东大会。 （二）召集人 本次股东大会的召集人为董事会。 关于召开 2023 年年度股东大会通知公告（提供网络投票） 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 （三）会议召开的合法性、合规性 本次股东大会的召集、召开、议案审议程序符合《公司法》和《公司章程》 的有关规定。 （四）会议召开方式 本次会议采用现场投票和网络投票相结合方式召开。 1、现场会议召开时间：2024 年 5 月 10 日 10:00。 2、网络投票起止时间：2024 年 5 月 9 日 15:00—2024 年 5 月 10 日 15:00。 登记在册的股东可通过中国证券登记结算有限责任公司（以下简称"中国结 算"）持有人大会网络投票系统对有关议案进行投票表决，为有利于投票意见的 顺利提交，请拟参加网络投票的投资者在上述时间内及早登录中国结算网上营业 厅（网址： ...

证券代码：835670 证券简称：数字人 公告编号：2024-028 山东数字人科技股份有限公司 (一)会计师事务所基本情况 信永中和会计师事务所（特殊普通合伙）成立于 2012 年 3 月，注册地址为 北京市东城区朝阳门北大街 8 号富华大厦 A 座 8 层，首席合伙人为谭小青先生。 截至 2023 年 12 月 31 日，信永中和合伙人（股东）数量为 245 人，注册会计师 1,656 人，签署过证券服务业务审计报告的注册会计师人数超过 660 人。2022 年度，信永中和审计业务收入（经审计）29.34 亿元，证券业务收入（经审计） 8.89 亿元，2022 年上市公司审计客户家数 366 家。 (二)聘任会计师事务所履行的程序 公司第三届董事会审计委员会第三次会议、第三届董事会第十五次会议及 2024 年第一次临时股东大会审议通过了《关于拟变更会计师事务所的议案》， 同意聘任信永中和为公司 2023 年度审计机构。 二、会计师事务所履职情况 信永中和对公司 2023 年度财务报告进行了审计，同时对公司内部控制执行 情况、募集资金存放与实际使用情况、非经营性资金占用及其他关联资金往来 情况等进行核查并出 ...

本人李增春作为山东数字人科技股份有限公司（以下简称"公司"）的独立 董事，能够严格按照《中华人民共和国公司法》《北京证券交易所股票上市规则 （试行）》《北京证券交易所上市公司持续监管指引第 1 号——独立董事》等有 关法律、法规及《山东数字人科技股份有限公司章程》《山东数字人科技股份有 限公司独立董事工作制度》的相关规定和要求，忠实、勤勉、尽责地履行相关职 责和义务，积极出席相关会议，及时了解公司的生产经营信息，关注公司的发展 状况，认真审议董事会各项议案，并针对相关议案发表独立性意见，充分发挥独 立董事的独立性和专业性作用，切实维护了公司和股东尤其是中小股东的利益。 现将本人在 2023 年度履行职责的情况汇报如下： 一、出席情况 （一）出席董事会、股东大会的情况 2023 年度，公司共召开 5 次董事会会议、2 次股东大会。本人出席上述会议 的情况如下： | 出席董 | 出席董事 | 委托出席 | 缺席董 | 出席股 | 出席股 | 现场工作 | | --- | --- | --- | --- | --- | --- | --- | | 事会次 | | 董事会次 | 事 会次 | 东 大会 | 东大会 | ...

证券代码：835670 证券简称：数字人 公告编号：2024-020 山东数字人科技股份有限公司 募集资金存放与实际使用情况的专项报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、募集资金基本情况 （一）募集资金金额及到位时间 根据中国证券监督管理委员会《关于核准山东数字人科技股份有限公司向不 特定合格投资者公开发行股票的批复》（证监许可〔2020〕2376 号），本公司由 主承销商国投证券股份有限公司（安信证券股份有限公司于 2023 年 12 月 8 日更 名为国投证券股份有限公司）采用余额包销方式，向不特定合格投资者公开发行 人民币普通股股票 8,000,000 股（含行使超额配售选择权所发新股），发行价为 每股人民币 12.50 元，共计募集资金 100,000,000.00 元，其中 2020 年 11 月 26 日公司向不特定合格投资者公开发行人民币普通股股票 6,956,522 股，每股发行 价为人民币 12.50 元，募集资金 86,956,525.00 元，坐扣承销和保荐费用 ...

证券代码：835670 证券简称：数字人 公告编号：2024-029 山东数字人科技股份有限公司 2023 年年度权益分派预案公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 为积极履行回报股东义务，与全体股东分享公司经营收益，在统筹考虑战略 发展目标及流动资金需求，保证公司健康、稳定、持续发展的前提下，山东数字 人科技股份有限公司（以下简称"公司"）拟实施 2023 年年度权益分派。 一、权益分派预案情况 根据公司 2024 年 4 月 17 日披露的 2023 年年度报告（财务报告已经审计）， 截至 2023 年 12 月 31 日，上市公司合并报表归属于母公司的未分配利润为 74,512,389.43 元，母公司未分配利润为 83,116,774.35 元。 公司本次权益分派预案如下：公司目前总股本为 106,182,400 股，以未分配 利润向全体股东每 10 股派发现金红利 0.60 元（含税）。本次权益分派共预计派 发现金红利 6,370,944.00 元。 公司将以权益分派实施时股权登 ...